Bone Marrow Transplantation

Article	Citations
Measurable residual disease for secondary acute myeloid leukemia prior to allogeneic hematopoietic cell transplantation: does it make a difference?	218
The 48th Annual Meeting of the European Society for Blood and Marrow Transplantation: Van Bekkum Awards	130
The 48th Annual Meeting of the European Society for Blood and Marrow Transplantation: Patient Advocacy – Poster Session (P613-P616)	80
The 48th Annual Meeting of the European Society for Blood and Marrow Transplantation: Nurses Group – Oral Session (NO001 – NO006)	73
The 48th Annual Meeting of the European Society for Blood and Marrow Transplantation: Statistical Symposium - Poster Session (P611-P612)	65
The 47th Annual Meeting of the European Society for Blood and Marrow Transplantation: statistical symposium-poster session (P188–P189)	61
The 47th Annual Meeting of the European Society for Blood and Marrow Transplantation: Nurses Group – Oral Session (NO001 – NO010)	59
The 47th Annual Meeting of the European Society for Blood and Marrow Transplantation: Psychiatry and Psychology Group - Oral Session (O170-O171)	57
T cell redirection as a new standard of care for relapsed multiple myeloma: impact on inpatient capacity, financial burden and infrastructural requirements in Germany	54
Chimeric antigen receptor T cell therapy in octogenarians with B cell lymphoma: a real-world US multicenter collaborative study	52
Outcomes of allogeneic hematopoietic stem cell transplantation versus intensive chemotherapy in patients with myeloid sarcoma: a nationwide representative multicenter study	52
High level serum IL-6 predicts occurrence of TA-TMA	51
Haploidentical hematopoietic stem cell transplantation for hematologic malignancies: a novel conditioning regimen with anti-T lymphocyte immunoglobulin instead of anti-thymocyte globulin for in vivo T	46
Novel factors to predict respiratory viral disease progression in allogeneic hematopoietic cell transplant recipients	45
Impact of thiotepa dose-intensity in primary diffuse large B-cell lymphoma of the central nervous system undergoing autologous hematopoietic cell transplant with thiotepa/carmustine conditioning	42
Graft engineering: how long can you wait, how low can you go, and pandemic readiness	42
Graft-versus-host disease and impact on relapse in myelofibrosis undergoing hematopoietic stem cell transplantation	42
The impact of individual comorbidities in transplant recipients receiving post-transplant cyclophosphamide	41
Significant detrimental impact of pre-transplant mogamulizumab on the post-transplant outcome with a short interval between the last mogamulizumab and transplantation	40
The 49th Annual Meeting of the European Society for Blood and Marrow Transplantation: Organising committee	39
The 49th Annual Meeting of the European Society for Blood and Marrow Transplantation: Statistical Symposium - Poster Session (P754-P757)	38
The 49th Annual Meeting of the European Society for Blood and Marrow Transplantation: Van Bekkum Awards	37
The 49th Annual Meeting of the European Society for Blood and Marrow Transplantation: Data Management Group – Poster Session (P725-P741)	36
The 49th Annual Meeting of the European Society for Blood and Marrow Transplantation: Patient Advocacy – Poster Session (P758-P762)	35
The 47th Annual Meeting of the European Society for Blood and Marrow Transplantation: Pharmacist Committee – Poster Session (P183-P186)	35

Evaluation of prognostic scores for respiratory syncytial virus infection in a French multicentre cohort of allogeneic haematopoietic stem cell transplantation recipients	34
Venetoclax is safe and tolerable as post-transplant maintenance therapy for AML patients at high risk for relapse	33
The effect of danger-associated molecular patterns on survival in acute graft versus host disease	32
Comparison of MEAM, MCEC and LEED high-dose chemotherapy followed by autologous stem cell transplantation in relapsed/refractory diffuse large B-cell lymphoma: data from the Japan Society for Hematopo	31
Survival outcomes between haploidentical stem cell transplantation and chemotherapy for blastic plasmacytoid dendritic cell neoplasm	29
In memory of Kristin Page 1974–2024	29
Intermediate-dose TBI/fludarabine conditioning for allogeneic hematopoietic cell transplantation in patients with peripheral T-cell lymphoma	29
Cytogenetic and molecular risk-driven conditioning intensity in acute myeloid leukemia patients undergoing stem cell transplantation with post-transplant cyclophosphamide: a study from the acute leuke	28
Early ribavirin reduce RSV symptoms duration in post-allogeneic stem cell transplant: challenges in symptoms duration assessment	28
Mild clinical course of SARS-coronavirus-2 infection early posttransplant in patients with adoptively transferred antibody response	27
Correction: Idelalisib exposure before allogeneic stem cell transplantation in patients with follicular lymphoma: an EBMT survey	26
Correction to: The coming of age of the pediatric EBMT criteria	25
A non-interventional study of microcirculation dynamics in allogeneic hematopoietic cell transplantation survivors compared to controls: evidence of impaired microvascular response regardless of conve	25
Cancers after hematopoietic cell transplantation for aplastic anemia—the importance of persistence	24
Donor-specific HLA antibodies associate with chronic graft-versus-host disease in haploidentical hematopoietic stem cell transplantation with post-transplant cyclophosphamide	23
Low Incidence of hepatic sinusoidal obstruction syndrome/veno-occlusive disease in adults undergoing allogenic stem cell transplantation with prophylactic ursodiol and low-dose heparin	23
Distinct clinico-biological features in AML patients with low allelic ratio FLT3-ITD: role of allogeneic stem cell transplantation in first remission	22
Correction to: Allogeneic hematopoietic cell transplantation for patients with TP53 mutant or deleted chronic lymphocytic leukemia: results of a prospective observational study	22
A real-life overview of a hematopoietic cell transplant program throughout a four-year period, including prospective registry, exclusion causes and final donor selection	22
Myths in wine and medicine	21
Outcomes of CD19 chimeric antigen receptor T cell followed by haploidentical hematopoietic stem-cell transplantation in relapsed/refractory B-cell acute lymphoblastic leukemia with IKZF1 deletion	21
Chronic graft-versus-host disease exacerbation after SARS-CoV-2 vaccination	20
Randomized phase 2 study of digital life coaching during transplantation for myeloma	20
Cytomegalovirus (CMV)-specific cytotoxic T lymphocyte therapy resolve CMV diseases and refractory CMV infections in paediatric recipients of allogeneic haematopoietic stem cell transplantation	20
Pre-engraftment Cytomegalovirus DNAemia after allogeneic hematopoietic stem cell transplantation and its impact on engraftment	20
‘Save the day with a Stem Cell Rescue’: Use of autologous hematopoietic stem cell boost for hematopoietic recovery after CAR T cell therapy	20
Triple post transplant cyclophosphamide (PTCY) based GVHD prophylaxis: HLA matched versus HLA haploidentical transplants	20
Therapeutic options for large B-cell lymphoma relapsing after CD19-directed CAR T-cell therapy	18
Treosulfan vs busulfan conditioning for allogeneic bmt in children with nonmalignant disease: a randomized phase 2 trial	18
Artificial intelligence methods to estimate overall mortality and non-relapse mortality following allogeneic HCT in the modern era: an EBMT-TCWP study	18
Efficacy of CD19 directed therapies in patients with relapsed or refractory large b-cell lymphoma relapsing after CD19 directed chimeric antigen receptor T-cell therapy	18
Prophylactic versus Preemptive modified donor lymphocyte infusion for high-risk acute leukemia after allogeneic hematopoietic stem cell transplantation: a multicenter retrospective study	18
Outcomes following second allogeneic haematopoietic cell transplantation in patients with myelofibrosis: a retrospective study of the Chronic Malignancies Working Party of EBMT	18
FLT3-ITDos and FLT3-ITDon’ts: navigating maintenance therapy in FLT3-ITD-positive acute myeloid leukemia following stem cell transplantation	18
Allogeneic haematopoietic cell transplantation for therapy-related myeloid neoplasms arising following treatment for lymphoma: a retrospective study on behalf of the Chronic Malignancies Working Party	17
Impact of minimal residual disease (MRD) in salvage autologous stem cell transplantation for relapsed myeloma: results from the NCRI Myeloma X (intensive) trial	17
Effect of high-dose chemotherapy plus stem cell rescue on the survival of patients with neuroblastoma modified by MYCN gene gain/amplification and remission status: a nationwide registration study in	17
Letermovir prophylaxis lowers the incidence of Non-CMV infections after allogeneic hematopoietic cell transplantation	17
Allogeneic stem cell transplantation for AML patients with RUNX1 mutation in first complete remission: a study on behalf of the acute leukemia working party of the EBMT	17
Fertility outcomes in patients desiring conception following autologous stem cell transplantation for hodgkin lymphoma using LACE conditioning	17
T cell receptor beta locus sequencing early post-allogeneic stem cell transplant identifies patients at risk of initial and recurrent cytomegalovirus infection	17
Validation of the transplant conditioning intensity (TCI) index for allogeneic hematopoietic cell transplantation	17
Correction to: Impact of depth of clinical response on outcomes of acute myeloid leukemia patients in first complete remission who undergo allogeneic hematopoietic cell transplantation	16
Cost-effectiveness analysis of allogeneic versus autologous stem cell transplant versus chemo-immunotherapy for early relapse of follicular lymphoma within 2 years of initial therapy	16
Prognostic impact of HLA supertype mismatch in single-unit cord blood transplantation	16
Graft-versus-host-disease prophylaxis with ATG or PTCY in patients with lymphoproliferative disorders undergoing reduced intensity conditioning regimen HCT from one antigen mismatched unrelated donor	16
Successful use of narsoplimab to treat allogeneic transplant-associated thrombotic microangiopathy while maintaining sirolimus	16
Finding a balance in reduced toxicity hematopoietic stem cell transplantation for thalassemia: role of infused CD3+ cell count and immunosuppression	16
Real-world utilisation of ASCT in multiple myeloma (MM): a report from the Australian and New Zealand myeloma and related diseases registry (MRDR)	16
Prognostic values of D816V KIT mutation and peri-transplant CBFB-MYH11 MRD monitoring on acute myeloid leukemia with CBFB-MYH11	15

OBITUARY- Riccardo Saccardi (20th April 1956–19th February 2024)	15
Overlap chronic GVHD is associated with adverse survival outcomes compared to classic chronic GVHD	15
Prognostic factors in 448 newly diagnosed multiple myeloma receiving bortezomib-based induction: impact of ASCT, transplant refusal and high-risk MM	15
Climate change in wine and haematology	15
Von Willebrand factor as a potential predictive biomarker of early complications of endothelial origin after allogeneic hematopoietic stem cell transplantation	15
Intensive monitoring of minimal residual disease and chimerism after allogeneic hematopoietic stem cell transplantation for acute leukemia in children	15
Improving nutritional status after allogeneic stem cell transplantation: results of phase 2 ALLONUT clinical trial	15
T-cell replete allogeneic stem cell transplant for mantle cell lymphoma achieves durable disease control, including against TP53-mutated disease	14
HLA-matched HSCT using targeted busulfan-based conditioning in children with primary hemophagocytic lymphohistiocytosis	14
Busulfan target exposure attainment in children undergoing allogeneic hematopoietic cell transplantation: a single day versus a multiday therapeutic drug monitoring regimen	14
Trends in utilization of stored cryopreserved autologous peripheral hematopoietic cells intended for a second (or beyond) autologous hematopoietic cell transplantation in patients with multiple myelom	14
Donor/recipient Rh-mismatched allogeneic hematopoietic stem cell transplantation: transfusion strategy and allo-immunization to red blood cell antigens	14
The HTLV-1 proviral status is a potential prognostic biomarker for adult T-cell leukemia-lymphoma treated with allogeneic stem cell transplantation	14
A high hematopoietic cell transplantation comorbidity Index (HCT-CI) does not impair outcomes after non-myeloablative allogeneic stem cell transplantation in acute myeloid leukemia patients 60 years o	14
Second haploidentical stem cell transplantation (HAPLO-SCT2) after relapse from a first HAPLO-SCT in acute leukaemia—a study on behalf of the Acute Leukaemia Working Party (ALWP) of the European Socie	14
Vampires, blood and wine	14
Prognostic value of the revised International Prognostic Scoring System five-group cytogenetic abnormality classification for the outcome prediction of hematopoietic stem cell transplantation in pedia	14
Long-term pulmonary function tests and complications following allogeneic stem cell transplantation	14
Incremental donor lymphocyte infusion to treat mixed chimerism after allogeneic stem cell transplantation in children with non-malignant diseases	14
Risk of infectious complications in adult patients after allogeneic hematopoietic stem cell transplantation depending on the site of central venous catheter insertion—multicenter prospective observati	14
Association between human herpesvirus-6 encephalitis and antiviral prophylaxis after allogeneic hematopoietic stem cell transplantation in the letermovir era	13
Successful treatment of refractory pure red cell aplasia in major ABO-mismatched allogeneic hematopoietic stem cell transplant with single agent Ibrutinib	13
Level of unique T cell clonotypes is associated with clonal hematopoiesis and survival in patients with lymphoma undergoing ASCT	13
Day 100 risk assessment tool predicts overall survival in allogeneic hematopoietic cell transplantation	13
Correction: Harmonizing definitions for hematopoietic recovery, graft rejection, graft failure, poor graft function, and donor chimerism in allogeneic hematopoietic cell transplantation: a report on b	13
Herpes simplex virus reactivation among hematopoietic stem cell transplant recipients: re-evaluating acyclovir dosage	13
Effect of prophylactic or pre-emptive use of tyrosine kinase inhibitors post-Allo SCT in bcr-abl positive acute lymphoblastic leukemia: a subanalysis of GITMO ph-positive ALL study	13
Autologous stem cell boost improves persistent immune effector cell associated hematotoxicity following BCMA directed chimeric antigen receptor T (CAR T) cell therapy in multiple myeloma	13
Haploidentical-cord blood stem cell transplantation versus haploidentical stem cell transplantation for non-CR acute leukemia patients: a multicenter study	13
Novel conditioning regimen for upfront haploidentical hematopoietic cell transplantation in children with severe aplastic anemia and donor-specific anti-HLA antibodies	13
Failure to reach hematopoietic allogenic stem cell transplantation in patients with myelodysplastic syndromes planned for transplantation: a population-based study	13
Improved outcomes of single-unit cord blood transplantation for acute myeloid leukemia by killer immunoglobulin-like receptor 2DL1-ligand mismatch	12
Abnormal body composition related to the early clinical adverse outcome after HSCT	12
Prognostic impact of chromosomal changes at relapse after allogeneic hematopoietic cell transplantation for acute myeloid leukemia or myelodysplastic syndrome	12
Basic characteristics and safety of donation in related and unrelated haematopoietic progenitor cell donors – first 10 years of prospective donor follow-up of Swiss donors	12
Infusion of haploidentical HSCs combined with allogenic MSCs for the treatment of ALL patients	12
Cancer incidence in healthy Swedish peripheral blood stem cell donors	12
Low-dose unfractionated heparin prophylaxis is a safe strategy for the prevention of hepatic sinusoidal obstruction syndrome after myeloablative adult allogenic stem cell transplant	12
Correction to: A SAS macro for estimating direct adjusted survival functions for time-to-event data with or without left truncation	12
CD14 positive cells accelerate hematopoietic stem cell engraftment	12
Health-related quality of life in pediatric patients with β-thalassemia major after hematopoietic stem cell transplantation	12
Bulsufan decreases the incidence of mixed chimaerism in HLA-matched donor transplantation for severe aplastic anaemia	12
Prospective phase II study of preemptive chimerism-driven reduction of immunosuppression after non-myeloablative conditioning—Eudract #: 2007-002420-15	12
Infective hyperammonaemic encephalopathy after allogeneic stem cell transplant	12
Low-dose post-transplant cyclophosphamide with low-dose antithymocyte globulin for prevention of graft-versus-host disease in first complete remission undergoing 10/10 HLA-matched unrelated donor peri	11
Exposure to antibiotics with anaerobic activity before respiratory viral infection is associated with respiratory disease progression after hematopoietic cell transplant	11
Comparison of fludarabine–melphalan and fludarabine–treosulfan as conditioning prior to allogeneic hematopoietic cell transplantation—a registry study on behalf of the EBMT Acute Leukemia Working Part	11
Treosulfan plus fludarabine versus TEAM as conditioning treatment before autologous stem cell transplantation for B-cell Non-Hodgkin lymphoma	11
Fludarabine- and low-dose cyclophosphamide-based conditioning regimens provided favorable survival and engraftment for unmanipulated hematopoietic cell transplantation from unrelated donors and matche	11
Beyond fludarabine: pentostatin plus cyclophosphamide are a well-tolerated alternative in reduced intensity conditioning	11
Efficacy of artesunate for treatment of cytomegalovirus reactivation post allogeneic haematopoietic stem cell transplants	11
Impact on outcomes of mixed chimerism of bone marrow CD34+ sorted cells after matched or haploidentical allogeneic stem cell transplantation for myeloid malignancies	11
Predictive value of next-generation sequencing-based minimal residual disease after CAR-T cell therapy	11
Adding 5-day decitabine to the conditioning regimen for haploidentical bone marrow transplantation in aplastic anaemia patients results in satisfactory clinical outcomes	11
Diversity, equity, and inclusion in transfusion medicine, blood donation, and blood and bone marrow transplantation: language matters	11
Grading bloodstream infection risk using citrulline as a biomarker of intestinal mucositis in patients receiving intensive therapy	11
The cellular composition and function of the bone marrow niche after allogeneic hematopoietic cell transplantation	11
DNA methylation in circulating leukocytes is a novel biomarker in multiple myeloma	11
Analysis of survival outcomes in haematopoietic cell transplant studies: Pitfalls and solutions	11
Donor genetic determinant of thymopoiesis rs2204985 impacts clinical outcome after single HLA mismatched hematopoietic stem cell transplantation	11
Patient-generated strategies for strengthening adherence to multiple medication regimens after allogeneic stem cell transplantation: a qualitative study	11
Novel conditioning regimen in upfront autologous stem cell transplantation in high-risk DLBCL	11
When is a chimaera not a chimaera?	11
Reduced-toxicity myeloablative conditioning regimen using fludarabine and full doses of intravenous busulfan in pediatric patients not eligible for standard myeloablative conditioning regimens: Result	11
Tandem hematopoietic stem cell transplant considerations in families with multiple siblings affected by DOCK8 deficiency	11
AI in wine and haematology	10
Combinatorial inhibition of Tec kinases BTK and ITK is beneficial in ameliorating murine sclerodermatous chronic graft versus host disease	10
On demand plerixafor is safe and effective for hematopoietic progenitor cell mobilization in patients with light chain amyloidosis at risk for mobilization failure with G-CSF alone	10
Trading tissues for freedom: incentivizing stem cell and solid organ donation in the incarcerated population	10
Validation of the CIBMTR scoring system in predicting early relapse of multiple myeloma after autologous hematopoietic cell transplant	10
Exploration of efficacy and safety of combined therapy of basiliximab with ruxolitinib for grade 3–4 steroid-refractory acute graft-versus-host disease: a registered clinical trial (NCT05021276)	10
Liver stiffness measurements predict Sinusoidal Obstructive Syndrome after hematopoietic stem cell transplantation	10
Benchmarking of survival outcomes following Haematopoietic Stem Cell Transplantation (HSCT): an update of the ongoing project of the European Society for Blood and Marrow Transplantation (EBMT) and Jo	10
Risk factors for a severe disease course in children with SARS-COV-2 infection following hematopoietic cell transplantation in the pre-Omicron period: a prospective multinational Infectious Disease Wo	10
Are syngeneic donors a viable donor option in allogeneic haematopoietic cell transplantation for MDS? A brief report on behalf of the Chronic Malignancies Working Party of the EBMT and review of curre	10
Autoimmune cytopenias following pediatric hematopoietic cell transplant	10
Autologous stem cell transplantation in adult patients with intermediate-risk acute myeloid leukemia in first complete remission and no detectable minimal residual disease. A comparative retrospective	10
Incidence of breakthrough COVID-19 in patients with hematological disorders who received pre-exposure prophylaxis with tixagevimab-cilgavimab: a retrospective study in Japan	10
Impact of standard-dose dipeptidyl peptidase-4 inhibitors on the incidence of graft-versus-host disease after allogeneic hematopoietic cell transplantation	10
Infection prevention practices among EBMT hematopoietic cell transplant centers: the EBMT Infectious Disease Working Party survey	10

Correction: An early post-transplant relapse prediction score in multiple myeloma: a large cohort study from the chronic malignancies working party of EBMT	10
Evaluation of venous thromboembolism prophylaxis protocol in hematopoietic cell transplant patients	10
Impact of mother donor, peripheral blood stem cells and measurable residual disease on outcomes after haploidentical hematopoietic cell transplantation with post-transplant cyclophosphamide in childre	9
Alemtuzumab-based conditioning regimen before hematopoietic stem cell transplantation in patients with short telomere syndromes: a retrospective study of the SFGM-TC	9
CAR-T cell therapy embarks on autoimmune disease	9
Autologous hematopoietic stem cell transplantation activity for lymphoma and multiple myeloma in China	9
Viral infections and risk, in Wine and Medicine	9
Gastrointestinal involvement refines prognosis in minnesota standard risk acute graft-vs.-host disease	9
Antibody responses to SARS-CoV2 vaccination in allogeneic hematopoietic stem cell transplant recipients	9
Correction: Shorter long-term post-transplant life expectancy may be due to prior chemotherapy for the underlying disease: analysis of 3012 patients with acute myeloid leukemia enrolled on 9 consecuti	9
Risk factors and long-term outcomes for human herpesvirus 6 encephalitis in the early period after allogeneic stem cell transplantation	9
Comparative analysis of reduced toxicity conditioning regimens between fludarabine plus melphalan and fludarabine plus busulfex in adult patients with acute lymphoblastic leukemia	9
Hematopoietic stem cell transplantation activity in China 2022–2023. The proportions of peripheral blood for stem cell source continue to grow: a report from the Chinese Blood and Marrow Transplantati	9
Standardized translations of the Lee Chronic GvHD Symptom Scale to 12 European languages: an EU COST Action cGvHD Eurograft project	9
Gender equality in wine and medicine	9
Challenges and successes in cellular therapies and CAR-T: insights from the 50th EBMT annual meeting	9
CD19 chimeric antigen receptor T-cell therapy as a bridge therapy for allogeneic hematopoietic stem cell transplantation in patients with relapsed Philadelphia chromosome-positive acute lymphoblastic	9
Satisfactory outcomes following a second autologous hematopoietic cell transplantation for multiple myeloma in poor stem cell mobilizers: a retrospective study on behalf of the Chronic Malignancies Wo	9
Lower incidence of acute graft-versus-host disease with post-transplantation cyclophosphamide compared to anti-thymocyte globulin in higher-risk myelodysplastic syndrome	9
Diversity in wine and haematology	9
Correction: Novel factors to predict respiratory viral disease progression in allogeneic hematopoietic cell transplant recipients	9
Wine without alcohol: medicine without doctors!	9
Comparison of HLA-mismatched unrelated donor transplantation with post-transplant cyclophosphamide versus HLA-haploidentical transplantation in patients with active acute myeloid leukemia	9
High activity of the new myeloablative regimen of gemcitabine/clofarabine/busulfan for allogeneic transplant for aggressive lymphomas	9
Trends in allogeneic transplantation for favorable risk acute myeloid leukemia in first remission: a longitudinal study of >15 years from the ALWP of the EBMT	9
Influence of comorbidities on outcome in 1102 patients with an allogeneic hematopoietic stem cell transplantation	9
Role of extracorporeal photopheresis in the management of acute and chronic graft versus disease: current status	9
A systematic review and meta-analysis of HHV-6 and mortality after hematopoietic cell transplant	9
Hematopoietic stem cell transplantation in children and adolescents with GATA2-related myelodysplastic syndrome	8
The impact of G-CSF alone vs G-CSF and cyclophosphamide mobilisation on autograft immune cell content in multiple myeloma	8
Efficacy of SARS-CoV-2 primary and booster vaccine doses in CAR-T recipients – targeting the target antigen	8
Off-the-shelf bone marrow-derived mesenchymal stem cell treatment for acute graft-versus-host disease: real-world evidence	8
NOTCH1 inhibition prevents GvHD and maintains GvL effect in murine models	8
HLA-identical related hematopoietic stem cell transplantation in severe sickle cell disease: age is not a barrier to successful outcome	8
Correction: The 49th Annual Meeting of the European Society for Blood and Marrow Transplantation: Pharmacist Committee—Poster Session (P716-P724)	8
The 50th Annual Meeting of the European Society for Blood and Marrow Transplantation: Physicians Award Winners (O001-O008)	8
Long term results of a prospective multicenter observational study on the use of anti-human T-lymphocyte immunoglobulin (ATLG) in unrelated donor transplantation (ATOS study)	8
KRD vs. VRD as induction before autologous hematopoietic progenitor cell transplantation for high-risk multiple myeloma	8
Ofatumumab as part of reduced intensity conditioning in high risk B-cell lymphoma patients: final long-term analysis from a prospective multicenter Phase-II Trial	8
Effect of early granulocyte-colony-stimulating factor administration in the prevention of febrile neutropenia and impact on toxicity and efficacy of anti-CD19 CAR-T in patients with relapsed/refractor	8
Use of high-dose mesna and hyperhydration leads to lower incidence of hemorrhagic cystitis after posttransplant cyclophosphamide-based allogeneic transplantation	8
Practice harmonization workshops of EBMT: an expert-based approach to generate practical and contemporary guidelines within the arena of hematopoietic cell transplantation and cellular therapy	8
Outcomes of allogeneic transplant in patients with DDX41 mutated myelodysplastic syndrome and acute myeloid leukemia	8
Abatacept for graft versus host disease prophylaxis in patients 60 years and older receiving mismatched unrelated donor transplantation for hematologic malignancies	8
Impact of haematopoietic stem cell transplantation for benign and malignant haematologic and non-haematologic disorders on fertility: a systematic review and meta-analysis	8
Antifungal prescription and stewardship in hematology and hematopoietic stem cell transplantation units worldwide: an international survey of EHA-SWG Infections in Hematology	8
An adapted European LeukemiaNet genetic risk stratification for acute myeloid leukemia patients undergoing allogeneic hematopoietic cell transplant. A CIBMTR analysis	8
Changes in Stem Cell Transplant activity and procedures during SARS-CoV2 pandemic in Italy: an Italian Bone Marrow Transplant Group (GITMO) nationwide analysis (TransCOVID-19 Survey)	8
Impact of conditioning regimen intensity on outcomes of second allogeneic hematopoietic cell transplantation for secondary acute myelogenous leukemia	8
Development and validation of an automated computational approach to grade immune effector cell-associated hematotoxicity	8
Age is no barrier for adults undergoing HCT for AML in CR1: contemporary CIBMTR analysis	8
Sequential administration of low dose 5-azacytidine (AZA) and donor lymphocyte infusion (DLI) for patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) in relapse after allogene	8
Prognostic factors in salvage transplantation for graft failure following allogeneic hematopoietic stem cell transplantation	8
Cellular therapy processing laboratory: a workforce hiring nightmare	8
Cardiorespiratory fitness and physical performance after childhood hematopoietic stem cell transplantation: a systematic review and meta-analysis	8
Prevalence of clonal hematopoiesis of indeterminate potential in patients with severe chronic graft-versus-host disease	8
Long term outcomes of the French ASTIS systemic sclerosis cohort using the global rank composite score	8
Immunogenicity of anti-SARS-CoV-2 Comirnaty vaccine in patients with lymphomas and myeloma who underwent autologous stem cell transplantation	8
Correction to: Ex vivo generated human T-lymphoid progenitors as a tool to accelerate immune reconstitution after partially HLA compatible hematopoietic stem cell transplantation or after gene therapy	8
CMV prophylaxis with letermovir significantly improves graft and relapse free survival following allogeneic stem cell transplantation	8
Correction: Cubic splines to model relationships between continuous variables and outcomes: a guide for clinicians	8
Hematopoietic cell transplantation and cellular therapies in Europe 2021. The second year of the SARS-CoV-2 pandemic. A Report from the EBMT Activity Survey	8
Addition of ruxolitinib to standard graft-versus-host disease prophylaxis for allogeneic stem cell transplantation in aplastic anemia patients	8
The 48th Annual Meeting of the European Society for Blood and Marrow Transplantation: Organising Committee	7
Cardiac complications associated with hematopoietic stem-cell transplantation	7
The 48th Annual Meeting of the European Society for Blood and Marrow Transplantation: Lectures	7
Busulfan plus cyclophosphamide vs. total body irradiation plus cyclophosphamide for allogeneic hematopoietic stem cell transplantation in patients with acute T lymphoblastic leukemia: a large-scale pr	7
The 50th Annual Meeting of the European Society for Blood and Marrow Transplantation: Van Bekkum Awards	7
Current combinatorial CAR T cell strategies with Bruton tyrosine kinase inhibitors and immune checkpoint inhibitors	7
Melphalan-based conditioning with post-transplant cyclophosphamide for peripheral blood stem cell transplantation: donor effect	7
The 47th Annual Meeting of the European Society for Blood and Marrow Transplantation: Lectures	7
Dynamics of neoantigen-specific T-cells in post-transplant relapse: do leukemia neoantigens elicit immune responses in transplant recipients?	7
Impact of TP53 alteration on allogeneic hematopoietic cell transplantation outcomes for myelodysplastic syndromes	7
The 48th Annual Meeting of the European Society for Blood and Marrow Transplantation: Pharmacist Committee – Oral Session (O156-O158)	7
The effect of weather on HCT and vines	7
High-dose thiotepa, in conjunction with melphalan, followed by autologous hematopoietic stem cell transplantation in patients with pediatric solid tumors, including brain tumors	7
Hypophosphatemia and pre-infusion thrombocytopenia as biomarkers for CRS and ICANS after CAR T therapy	7
The 50th Annual Meeting of the European Society for Blood and Marrow Transplantation: Physicians - Oral Session (O009-O154)	7
Safety and efficacy of the ROCK-2-inhibitor Belumosudil in cGvHD treatment - a retrospective, German-Swiss multicenter real-world data analysis	7
Impact of age on outcome of CAR-T cell therapies for large B-cell lymphoma: the GLA/DRST experience	7
The 50th Annual Meeting of the European Society for Blood and Marrow Transplantation: Pharmacist Committee – Poster Session (P762-P770)	7
Physical fitness and childhood hematopoietic stem cell transplantation: a call to action	7
Enhanced antileukemic effect of NKp30b isoform of donor-derived NK cells infused after HLA-haploidentical allogeneic hematopoietic cell transplantation in high-risk AML and MDS	7
Correction: Reduced prefrontal cortex and sympathetic nervous system activity correlate with fatigue after aHSCT	7
Letermovir for Cytomegalovirus infection in pediatric patients undergoing allogenic hematopoietic stem cell transplantation: a real-life study by the Infectious Diseases Working Group of Italian Assoc	7
The 48th Annual Meeting of the European Society for Blood and Marrow Transplantation: Physicians - Oral Sessions (O009-O155)	7
Increased Epstein-Barr virus reactivation but similar incidence of post-transplant lymphoproliferative disorders due to pre-emptive rituximab therapy following allogeneic hematopoietic stem cell trans	7
Efficacy and prognostic assessment of chemotherapy-bridged transplantation in pediatric patients with advanced myelodysplastic syndromes	7
Dynamics of recent thymic emigrants in pediatric recipients of allogeneic hematopoetic stem cell transplantation	7
Trends in allogeneic haematopoietic cell transplantation for myelofibrosis in Europe between 1995 and 2018: a CMWP of EBMT retrospective analysis	7
Real-world use of defibrotide for veno-occlusive disease/sinusoidal obstruction syndrome: the DEFIFrance Registry Study	7
The 47th Annual Meeting of the European Society for Blood and Marrow Transplantation: Pharmacist Committee – Oral Session (O172-O174)	7
The 47th Annual Meeting of the European Society for Blood and Marrow Transplantation: Welcome Address	7
Real-world collection of secondary myeloid neoplasms after CD19 CAR-T cell therapy: first report of the ClonHema study	7
The 48th Annual Meeting of the European Society for Blood and Marrow Transplantation: Reviewers	7